Your session is about to expire
← Back to Search
Neratinib + Capecitabine for Breast Cancer
Study Summary
This trial is testing a new cancer treatment for patients whose tumors are HER2-negative, but show abnormal HER2 activity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.It has been at least 28 days since my last fulvestrant dose.My side effects from previous treatments have mostly gone away.I have not had whole-brain radiotherapy in the last 3 months.I understand this study is experimental and I can sign the consent form.My breast cancer is confirmed to be HER2 negative.I am post-menopausal, surgically sterile, or will use birth control during and for 6 months after the study.My doctor thinks I might need treatment that affects my whole body now or later.I have a serious heart condition.It has been over 21 days since my last targeted cancer treatment.I have a tumor outside my brain that can be biopsied.I am able to get out of my bed or chair and move around.It has been over 30 days since my last experimental cancer treatment or immunotherapy.I am either male or female.My cancer has spread to my brain recently or is getting worse.My tumor shows abnormal HER2 activity based on the CELsignia test.I have triple negative breast cancer and haven't had specific cancer treatments.I have ER+ breast cancer and was treated with CDK4/6 inhibitors and hormone therapy for advanced disease.I have been treated with capecitabine for my breast cancer that has spread.I cannot absorb pills due to my stomach or intestine condition.It's been over 14 days since my last chemotherapy dose, except for capecitabine.My blood, liver, kidneys, and clotting functions are all within normal ranges.I am willing to have a biopsy for research purposes.I have a new or growing brain tumor larger than 5 mm.I am healthy enough to have a biopsy.It's been over a week since my last hormone therapy, except for fulvestrant.My blood pressure is often above 160/110 mmHg, or I struggle to control it with medication.It's been over a week since my last radiation treatment and I've recovered from any immediate side effects.I am not taking any strong or moderate drugs that affect enzyme CYP3A4.My HER2 test results were unclear.I have or might have cancer spread to the lining of my brain and spinal cord.My tumor shows normal HER2 activity.I have had a blood clot in my lung or leg in the last 3 months.I understand this study is experimental and I can sign the consent form.I have not had major surgery in the last 10 days.I have inflammatory bowel disease with significant diarrhea.You have visible signs of cancer that has spread to the brain in imaging tests.I have no cancer recurrence in the last 2 years, except for certain skin cancers or treated cervical cancer.I have bleeding problems or take blood thinners that could make a biopsy risky.Your heart's pumping ability is normal.
- Group 1: Experimental: Capecitabine and Neratinib.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are capecitabine and neratinib most commonly used to treate?
"Cancerous growths such as malignant neoplasms, pancreatic endocrine carcinoma, and colorectal carcinoma can be managed through the administration of capecitabine and neratinib."
How many people are being chosen for this clinical trial?
"The trial is currently seeking 22 participants from 1 site, as stated on clinicaltrials.gov. This information is accurate as of the trial's last update on September 23rd, 2022."
Are there any risks that come with taking capecitabine and neratinib?
"While there is some data supporting the safety of the experimental combination of capecitabine and neratinib, there is currently no evidence to suggest that the drug combo is effective. Our team scores it a 2."
What are the findings of other academic research projects that have included capecitabine and neratinib?
"Currently, 370 different clinical trials are investigating the combination of capecitabine and neratinib. 130 of those trials are currently in Phase 3. While most of the research is being conducted in Melbourne, Victoria, there are 13131 total locations running these studies."
Share this study with friends
Copy Link
Messenger